New NVHR Fact Sheet: Expanding HCV Treatment Among People Who Inject Drugs

Share this

The primary risk factor for new hepatitis C virus (HCV) infections in the United States is injection drug use, with an estimated 80% of acute HCV cases reporting a history of injecting drugs.  Providing curative treatment to people who inject drugs will not only reduce the prevalence of HCV within this population, but it is a key public health strategy to prevent further HCV transmission.  Despite the availability of highly effective HCV medications with a cure rate of over 90%, people who inject drugs are often denied treatment due to stigma and restrictive health policies.  With this new fact sheet, NVHR aims to eliminate misconceptions about HCV treatment among people who inject drugs and promote advocacy for the expansion of treatment services. 


View and download the fact sheet here